• Early Immunosuppressive Treatment May Prevent ILD Progression in SSc Patients, Study Suggests
  • Ofev Granted FDA Breakthrough Therapy Status for Progressive Interstitial Lung Disease Treatment
  • Experts Issue Recommendations for Managing Juvenile Localized Scleroderma
  • With Scleroderma, Exercise Comes at a Cost
  • Phase 2 Study of Bermekimab in Treating Scleroderma Enrolls 1st Patient
  • Estrogen Blocks Profibrotic Signals Driving Scleroderma, Study Suggests
  • Raynaud’s Association Joins October Awareness Campaign, Notes Scleroderma Link
  • Finding the Glimmer of Gold Amid the Sludge of Scleroderma
  • Modified Inflammatory Protein May Help Reverse Fibrosis in Scleroderma, Mouse Study Suggests
  • NORD 2019 Rare Disease Summit Set for Oct. 21-22 in Washington, DC
  • Processa Enters Agreement to Develop HT-100 as Possible Fibrotic Disease Treatment
  • FDA Approves Ofev to Slow Lung Function Decline in SSc-ILD Patients